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Abstract
Background: Plasmodium vivax is the second most prevalent malaria parasite affecting more than
75 million people each year, mostly in South America and Asia. In addition to major morbidity this
parasite is associated with relapses and a reduction in birthweight. The emergence and spread of
drug resistance in Plasmodium falciparum is a major factor in the resurgence of this parasite. P. vivax
resistance to drugs has more recently emerged and monitoring the situation would be helped, as
for P. falciparum, by molecular methods that can be used to characterize parasites in field studies
and drug efficacy trials.
Methods: Practical PCR genotyping protocols based on polymorphic loci present in two P. vivax
genetic markers, Pvcs and Pvmsp1, were developed. The methodology was evaluated using 100 P.
vivax isolates collected in Thailand.
Results and Discussion: Analysis revealed that P. vivax populations in Thailand are highly diverse
genetically, with mixed genotype infections found in 26 % of the samples (average multiplicity of
infection = 1.29). A large number of distinguishable alleles were found for the two markers, 23 for
Pvcs and 36 for Pvmsp1. These were generally randomly distributed amongst the isolates. A total of
68 distinct genotypes could be enumerated in the 74 isolates with a multiplicity of infection of 1.
Conclusion: These results indicate that the genotyping protocols presented can be useful in the
assessment of in vivo drug efficacy clinical trials conducted in endemic areas and for epidemiological
studies of P. vivax infections.
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Background
Plasmodium vivax is globally distributed and is the domi-
nant species in many countries. Infection by this species is
generally regarded as benign and mortality is a rare out-
come. 1.2 billion inhabitants of the South East Asian and
Pacific countries are at risk from malaria transmission,
representing about a third of world population exposed to
Plasmodium parasites [1,2]. Most of the populations at risk
in these countries (corresponding to the WHO regional
groupings SEARO and WPRO) reside in hypoendemic
and mesoendemic areas, where half of the recorded infec-
tions are due to P. vivax, suggesting that the global burden
of vivax malaria morbidity must be close to that of falci-
parum malaria. It has recently been established that P.
vivax  infections during pregnancy are associated with
reduced birthweight [3], and thereby, increase the risk of
neonatal deaths. Thus, the urgency to develop and imple-
ment measures to control P. vivax should equal that
attending P. falciparum.
The emergence and global spread of P. falciparum parasites
resistant to chloroquine and pyrimethamine – sulfadox-
ine has led to an increase in morbidity and mortality [4],
forcing many countries to abandon these relatively cheap
drugs. Recent reports of P. vivax resistance to these drugs
[5-13] are of concern and steps to restrict the emergence of
drug resistance need to be taken. A critical component of
malaria control is surveillance for resistance. Despite
some disadvantages, in vitro assessment of the susceptibil-
ity of P. falciparum to antimalarial drugs provides a rapid
means to monitor general levels of drug resistance.
Although protocols to culture P. vivax parasites  ex-vivo
have been developed [14,15], they are still unsuited for
routine assays. Thus, well conducted clinical trials, an
essential component of resistance monitoring, remain the
only alternative for P. vivax. However, in vivo drug efficacy
studies conducted in endemic areas are to some extent
compromised by their inability to distinguish true recru-
descences, i.e. treatment failures, from re-infections which
become clinically or parasitologically manifest during the
follow-up period, i.e. treatment successes. This has been
largely overcome for P. falciparum by the application of
genotyping based on well characterized polymorphic
regions within the gene encoding msp1, msp2 and glurp
[16].
A similar approach has not been adopted for P. vivax, a
parasite species less well-studied at the molecular level
than P. falciparum [17]. Four polymorphic P. vivax single
copy genes have been independently used for molecular
epidemiological studies: Pvgam1 coding for a gametocyte
antigen,  Pvcs  coding for the circumsporozoite protein,
Pvmsp1  and  Pvmsp3α   coding for the merozoite surface
proteins 1 and 3 alpha, respectively. Amplification of
Pvgam1 was found to be associated with artefacts [18] and
should thus be excluded as a genetic marker. The suitabil-
ity of Pvmsp3α  as a marker has been recently validated
[19]. The extent of diversity found for the remaining two
genes was mainly established through sequencing of
amplified fragments.
The objective of this work was to develop field applicable
methods of genotyping which could also complement
clinical trials in vivax malaria. The highly polymorphic
genes Pvcs and Pvmsp1 were therefore selected to develop
protocols for polymerase chain reaction (PCR) amplifica-
tion and subsequent analysis of the polymorphic regions.
The methodology was then assessed and validated with
samples obtained from patients who acquired a P. vivax
infection in Thailand.
Materials and Methods
Blood samples
Blood samples were collected from adult patients with
symptomatic P. vivax malaria admitted to the Bangkok
Hospital for Tropical Diseases, Thailand between 1995 to
1998 (n = 100). All patients gave fully informed consent
to enrolment in these studies which were approved by the
Ethics committee of the Faculty of Tropical Medicine,
Mahidol university. Diagnosis was established by micros-
copy at the malaria laboratory through examination of
thin and thick blood smears, stained with Field's stain.
The blood samples were kept at -30°C until DNA
extraction.
DNA template preparation
DNA was purified from blood sample using the commer-
cially available DNA Blood Kit (QIAGEN, Germany). The
final volume of the DNA solution used as a template for
the amplification reactions was such that 1 µL corre-
sponded to 5 µL of whole blood. Confirmation of the
microscopic diagnosis as P. vivax and testing for the pres-
ence of other Plasmodium species were achieved by a pre-
viously described PCR-based protocol [20].
Amplification protocols
In order to increase the sensitivity of amplification, a
nested or semi-nested PCR approach was adopted for all
the fragments amplified except for one of the three Pvmsp1
regions. Oligonucleotide primers were designed using
published sequences of Pvcs  and of Pvmsp1  (their
sequences are presented in Table 1). The optimal Mg2+
concentrations, annealing temperatures and numbers of
cycles were individually determined for the different
primer pairs and are presented in Table 1.
All amplification reactions were carried out in a total vol-
ume of 20 µL and in the presence of 10 mM Tris-HCl, pH
8.3, 50 mM KCl, 250 nM of each oligonucleotide primers,
125  µM of each of the four dNTPs, and 0.4 units ofMalaria Journal 2005, 4:20 http://www.malariajournal.com/content/4/1/20
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AmpliTaq polymerase (Perkin Elmer Cetus, USA). Pri-
mary amplification reactions were initiated with one µL of
the template genomic DNA prepared from the blood sam-
ples, and the one µL of the product of these reactions was
used to initiate the secondary amplification reactions. The
cycling parameters for PCR were as follows: an initial
denaturation step at 95°C for five minutes preceded the
cycles of annealing at a temperature defined for each
primer pair (Table 1) for two minutes, extension at 72°C
for two minutes, and denaturation at 94°C for one
minute. After a final annealing step followed by five min-
utes of extension, the reaction was stopped. PCR products
were stored at 4°C until analysis.
The lack of cross-contamination was monitored by the
inclusion of multiple, randomly distributed, negative
control samples (human DNA or no template) in each
amplification run. A subset of the samples were analysed
in triplicate in order to confirm the consistency of the
results obtained.
Analysis of the amplification product
The DNA fragments obtained following PCR were ana-
lysed by electrophoresis in agarose gels. For direct analysis
of the fragments, 10 µL of the amplified PCR product were
mixed with two µL of loading buffer and applied to 2 %
agarose gels. For restriction fragment length polymor-
phism analysis of the PCR products (PCR-RFLP), 10 µL of
the amplified PCR product were first digested with a
restriction enzyme (New England Biolabs Inc., UK)
according to the suppliers specifications, for three hours
in a total volume of 20 µL, before adding five µL of load-
ing buffer and applying to 1.5 % or 1.8 % agarose gels.
Electrophoresis was performed in TBE buffer, and the
DNA was visualised on an ultraviolet transilluminator fol-
lowing ethidium bromide staining. The size of the ampli-
fied fragments was estimated by comparison to a 100 bp
ladder marker set.
Selected amplified fragments were purified using
QIAquick gel extraction kits (QIAGEN, Germany) and
cloned using the TOPO -TA Cloning kit (Invitrogen,
U.S.A.). Plasmid DNA containing the fragment was puri-
fied from positive bacterial colonies using the QIAquick
Miniprep spin kit (QIAGEN, Germany) and sequenced
using an ABI automated sequencer. Sequence alignments
were performed using the Gene Jockey II program (Bio-
soft, United Kingdom).
Results
Specificity and sensitivity of the amplification reactions
Primers specific to Pvcs  and  Pvmsp1  were designed to
hybridize to sequences conserved in all variants known at
that time. The specificity of all the primer pairs was con-
firmed since amplification products were only observed
when P. vivax DNA was included in the reaction, but not
when genomic DNA from P. falciparum,  Plasmodium
malariae, Plasmodium ovale or humans were used as a tem-
plate. A set of a 10-fold serial dilution of a template pre-
pared from a blood sample containing P. vivax only,
calibrated using a previously described protocol [20], was
used to assess the sensitivity of the reactions. Consistent
Table 1: Primers used for genotyping P. vivax parasites.
Gene Primer Sequencea mM Mg2+ b Annealing °C b Cyclesb
1st 2nd 1st 2nd 1st 2nd
Pvcs VCS-OF ATGTAGATCTGTCCAAGGCCATAAA 1 58 25
VCS-OR TAATTGAATAATGCTAGGACTAACAATATG 1 58 25
VCS-NF GCAGAACCAAAAAATCCACGTGAAAATAAG 1 62 30
VCS-NR CCAACGGTAGCTCTAACTTTATCTAGGTAT 1 62 30
Pvmsp1 F1 VM1-O1R CCACTCCATGAAACTGAAGTGTTTA 2 68 25
VM1-N1F CGATATTGGAAAATTGGAGACCTTCATCAC 2 2 68 68 25 30
VM1-N1R CTTTTGCGCCTCCTCCAGCTGGCTCGTGT 2 68 30
Pvmsp1 F2 VM1-O2F GATGGAAAGCAACCGAAGAAGGGAAT 1 50 25
VM1-O2R AGCTTGTACTTTCCATAGTGGTCCAG 1 1 50 64 25 35
VM1-N2F AAAATCGAGAGCATGATCGCCACTGAGAAG 1 64 35
Pvmsp1 F3 VM1-3F CAAGCCTACCAAGAATTGATCCCCAA 1 66 42
VM1-3R ATTACTTTGTCGTAGTCCTCGGCGTAGTCC 1 66 42
a Sequences are provided 5'- to 3'-end.p
b The two columns indicate conditions for the primary and secondary amplification reactions.Malaria Journal 2005, 4:20 http://www.malariajournal.com/content/4/1/20
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detection of 10 parasite genomes was achieved for Pvcs-
specific primers, and of 50 parasite genomes for Pvmsp1-
specific primers. These levels of sensitivity were in agree-
ment with subsequent analyses of samples harbouring a
known number of parasites.
Genotyping using Pvcs
The circumsporozoite protein gene of P. vivax, as for other
Plasmodium species, comprises a central repetitive domain
flanked by two conserved domains. The majority of varia-
tions observed in Pvcs occur in the repeat region and the
immediate pre- and post-repeat sequences. Thus the gen-
A. Schematic representation of the Pvcs gene, which consists of a conserved region (blank box) flanking a repeated region (grey  box) which is itself flanked by pre- and post-repeat specific sequences (cross-hatched boxes) Figure 1
A. Schematic representation of the Pvcs gene, which consists of a conserved region (blank box) flanking a repeated region (grey 
box) which is itself flanked by pre- and post-repeat specific sequences (cross-hatched boxes). The bold horizontal line repre-
sents the PCR-amplified fragment used for further analysis. B. Example of the fragments (denoted A to G) of distinct size 
observed in different isolates, as single or as mixed infections (some lanes were not labelled because of lack of space). C. Frag-
ments digested (D) or undigested (U) with Alu I or BstN I, two restriction enzymes with multiples sites in VK 210 type or 
VK247 type repeat sequences, respectively. Digestion cuts the fragment in small fragments of less than 150 bp in size. D. PCR-
RFLP using specific restriction enzymes analysis for the presence/absence (yes/no) of specific pre- and post-repeat sequences in 
fragments carrying the VK210 or VK247 type repeats. Undigested fragments are denoted by (U) and Pr and Po denote digests 
to determine the presence of pre- and post-repeat sequence types, respectively. A 100 bp ladder, where the 600 bp band 
stains most intensely, was used a molecular weight marker (M) for all the gels.Malaria Journal 2005, 4:20 http://www.malariajournal.com/content/4/1/20
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otyping strategy was focused on an amplified fragment
spanning these regions (Fig. 1A). In a given parasite line,
the repetitive domain is composed of a 27 bp element
repeated a variable number of times. Variations in the
number of repeated elements result in size polymor-
phisms amenable to detection by electrophoresis. Seven
allelic types distinguishable by size were observed in the
Thai P. vivax isolates analysed (Fig. 1B), a number consist-
ent with the variations in the number of repeat elements
(15 to 21) previously observed for Pvcs [21,22]. In P. vivax,
two types of repeat elements are found, VK210 and VK247
[23], and a given Pvcs gene will exclusively bear either the
VK210 type (type I repeats based on GDRADGQPA) or
the VK247 type (type II repeats based on ANGAGNQPG).
In order to differentiate between amplified fragments car-
rying the VK210 from those carrying the VK247 repeat ele-
ment, the exclusive presence of Alu I recognition sites in
the VK210-type and of Bst  NI recognition sites in the
VK247-type repeated sequences were exploited. Thus, fol-
lowing digestion with the appropriate enzyme, the ampli-
fied fragments are degraded into fragments of < 150 bp,
easily distinguishable from the original fragments of >
700 bp (Fig. 1C). In this manner the PCR fragments
obtained from an isolate can be grouped by size and by
repeat type.
In order to increase the genotyping resolution of Pvcs as a
marker, so as to subdivide the P. vivax population into a
larger number of Pvcs allelic types, sequence variations
previously observed in the pre- and post-repeat regions
[24] were used to develop an additional PCR-RFLP proto-
col (Fig. 1D). For some Pvcs genes, the pre-repeat consists
of the Region I sequence (KLKQP) that directly abuts the
repeated region, while for others amino acid residues are
inserted between the two regions, namely a T, V or A resi-
due for VK210-type Pvcs genes, or ED residues for VK247-
type Pvcs genes. The Scr FI restriction endonuclease cuts
VK210-type Pvcs fragments that do not have the T/A/V
insertion following Region I, thus shortening them by 41
bp. VK247-type Pvcs bearing the ED insertion after Region
I are cut by the Mbo II restriction endonuclease and the
amplified fragment is thereby shortened by 55 bp. For the
post-repeat region, a 36 bp insertion has been found for
some VK210-type Pvcs. This insertion harbours a recogni-
tion site for the Bbs I enzyme, and digestion truncates the
corresponding PCR fragments by 115 bp.
Table 2: Frequency of Pvcs allelic variants classed by size, repeat type and presence of pre- and post-repeat insertions.
Allele Sizea Pre-repeatb Post-repeatb n Frequencyc
VK210a AY e s N o1 0.008
VK210b BY e s N o8 0.067
VK210c CY e s N o7 0.058
VK210d CN o N o1 0.008
VK210e CY e s Y e s1 0.008
VK210f DY e s N o2 4 0.200
VK210g DN o N o1 0 0.083
VK210h DN o Y e s4 0.033
VK210i EY e s N o2 2 0.183
VK210j EN o N o7 0.058
VK210k EN o Y e s3 0.025
VK210l FN o N o2 0.017
VK210m FN o Y e s1 0.008
VK210n FY e s N o2 0.017
VK210o BN o N o2 0.017
VK210p BN o Y e s2 0.017
VK210q GN o N o1 0.008
VK210r CN o Y e s1 0.008
VK247a BI n N D 3 0.025
VK247b CI n N D 2 0.017
VK247c DI n N D 4 0.033
VK247d BN o N D1 0.008
VK247e EN o N D1 0.008
a The fragments were assigned to different size bins (labelled A to G in decreasing order) by visual inspection.
b "Yes" and "No" respectively denote the presence or absence of insertions in the pre- and post-repeat regions as ascertained by PCR-RFLP 
analysis.
c Calculated for the 120 bands observed in the 100 Thai isolates analysed.Malaria Journal 2005, 4:20 http://www.malariajournal.com/content/4/1/20
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Genotyping of the 100 P. vivax isolates collected from
Thailand was achieved successfully using the protocols
described above. In total, parasites with a Pvcs bearing the
VK210 type repeats only were found in 90 isolates (repre-
senting seven size polymorphisms). Parasites with a Pvcs
bearing the VK247-type repeats only were found in nine
isolates (representing only three size polymorphisms),
and in one isolate parasites of both types were found.
Thus, 10 different allelic forms of Pvcs were detected by
simple analyses of the fragment size and repeat type.
When associated with RFLP analysis of the pre- and post-
repeat types, these could be divided into 23 different
allelic types (Table 2), 18 for the VK210 type and five for
the VK247 type. Mixed genotype infections were found in
20 of the isolates, for each of which the multiplicity of
infection (MOI), i.e. the total number of different allelic
types observed, was two. Thus, for the samples analysed,
a total of 120 bands were observed, with an mean MOI of
1.2. The allelic variants were generally randomly distrib-
uted between the 120 bands; the highest frequencies, 0.2
and 0.18, were found for VK210k and VK210n, respec-
tively (Fig 2).
Genotyping using Pvmsp1
The Pvmsp1 gene encodes a polypeptide of about 1,720
amino acids [25,26], and sequence comparison revealed
13 regions of interallele conserved blocks and variable
blocks [27]. Three main regions of sequence divergence
were found through comparison of the full length Pvmsp1
sequences from two distinct P. vivax lines (Sal-1 and
Belem). Three segments (labelled F1 to F3) corresponding
to these regions were thus amplified for further analysis
(Fig. 3A).
For the 100 Thai P. vivax isolates, five distinguishable size
variants were observed for F1 (ca. 350 bp – 450 bp), and
four for F3 (ca. 250 bp – 350 bp), but only two were
observed for the larger (ca. 1087 bp -1150 kb) F2 segment
(Fig. 3B). One allelic variant dominated in frequency for
each of the three amplified segments (Table 3): band C for
F1 (42 % of the bands observed), band A for F2 (78 %)
and band D for F3 (76 %). Mixed genotype infections
were observed infrequently and only for the F1 (n = 3, 2
MOI of 2 and 1 MOI of 3) and for the F3 (n = 6, 4 MOI of
2 and 2 MOI of 3) segments.
A selection of amplified product from F1 (n = 18) and F3
(n = 8) representative of all the size variants were
sequenced and compared to previously published
sequences (Fig. 4). The number of distinct F1 variants was
found to be higher than that revealed by electrophoretic
separation, since 11 different allelic variants were
observed for the 18 fragments derived from the Thai iso-
lates. Sequence differences were observed within the vari-
ants assigned to the B, D or E size classes. Some of the
bands within each class might be distinguished by the use
of higher resolution agarose gels, though others had the
same size and only exhibited subtle sequence differences.
Allele frequency of the distinct allelic variants of Pvcs observed in the 100 isolates from Thailand Figure 2
Allele frequency of the distinct allelic variants of Pvcs observed in the 100 isolates from Thailand. Allelic types were defined 
according to repeat type (VK210 or VK247), fragment size and the presence or absence of defined pre- and post-repeat 
sequences.Malaria Journal 2005, 4:20 http://www.malariajournal.com/content/4/1/20
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A similar pattern was observed for the F3 fragments,
where sequencing distinguished six different variants.
The F2 segment, which was comparatively poorly poly-
morphic in size in the Thai isolates, encompassed regions
established as polymorphic in previous studies [27]. An
RFLP strategy was thus adopted to distinguish between the
different allelic variants. The restriction endonucleases Alu
I and Mnl I which recognize multiple sites in F2, were used
to reveal extensive polymorphism at the nucleotide level
(Fig. 3C). Thus, nine different Alu I and eight different Mnl
I RFLP patterns were observed in the 100 Thai isolates
(Table 3). The occurrence of patterns indicative of partial
digestion, or the presence of mixed F2 genotypes in indi-
vidual samples were excluded since the sum of the RFLP
fragments' sizes was not found to be greater than that of
the uncut product for any isolate and the patterns
observed were not unique to isolates where mixed
genotypes were detected through size polymorphism of
the F1 or F3 segments. When the data from both analyses
(size and RFLP) were combined, 36 Pvmsp1 F2 allelic var-
iants could be differentiated (Table 4). When the fre-
quency of the allelic variants was considered individually
for the two RFLP patterns, 50 % and 38 % of the isolates
were of a single Alu I- and Mnl I-classified allelic variant,
respectively. The remaining isolates were randomly dis-
tributed between the different variants (Fig. 5A). How-
ever, by combining the results for both restriction
enzymes, the most dominant allele was found in only 27
% of the isolates (Fig. 5B), while the remainder were
found at lower frequency (5 % or less).
Two locus genotyping
When the genotype analyses from the four polymorphic
regions of the two genes were combined, the 100 isolates
collected from Thai patients proved to be highly geneti-
A. Schematic representation of the Pvmsp1 gene for the localization of interallele conserved blocks (blank boxes) and variable  blocks (black boxes) Figure 3
A. Schematic representation of the Pvmsp1 gene for the localization of interallele conserved blocks (blank boxes) and variable 
blocks (black boxes). The position of the three amplified segments (F1, F2 and F3) is indicated by the horizontal bold lines. B. 
Gel electrophoresis of PCR products of a selection of fragments, corresponding to the three segments, amplified from differ-
ent isolates. The molecular size of the largest and smallest bands are indicated. C. Analysis of the diversity of the F2 segment by 
PCR-RFLP using Alu I or Mnl I. A selection of lanes is labelled to indicate the type of variant observed (corresponding to the 
nomenclature in Table 3). A 100 bp ladder was used a molecular weight marker (M) for all the gels.Malaria Journal 2005, 4:20 http://www.malariajournal.com/content/4/1/20
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cally diverse. Mixed genotype infections were detected in
26 of the isolates, mainly through the Pvcs gene (n = 20).
Only one of the isolates identified as mixed genotype
infections by Pvmsp1 (n = 7) was classed as such by Pvcs
analysis. The mean MOI for isolates with a mixed geno-
type was 2.11, and that for the complete set of isolates was
1.29.
There were 74 isolates where a single genotype was
detected after full analysis of the Pvcs and Pvmsp1 markers.
Comparison of the genotyping patterns obtained for these
isolates allows to ascertain the relative contribution of the
polymorphic loci to distinguish between P. vivax popula-
tions. When the complete genotyping analyses are taken
into account, a total of 68 distinct genotypes are enumer-
ated. Sixty-three genotypes were observed in only one iso-
late, with a maximum of three isolates sharing the same
genotype (highest genotype frequency = 0.040). No evi-
dence for linkage disequilibrium could be detected when
Pvcs and Pvmsp1 were considered. If the results from the
Pvmsp1 F1 segment are omitted from the analysis, 58 dis-
tinct genotypes would be found, with a maximum of four
isolates sharing the same genotype (highest genotype fre-
quency = 0.054). Incremental omission of the Pvmsp1 F3
segment followed by that of the Pvcs pre- and post-repeat
PCR-RFLP results would reduce the total number of dis-
tinct genotypes to 55 with four isolates sharing the same
genotype (highest genotype frequency = 0.054), and to 49
with seven isolates sharing the same genotype (highest
genotype frequency = 0.095), respectively.
Discussion
Populations of P. vivax, like those of other Plasmodium
species, comprise genetically distinct lines that exhibit
diversity in a number of factors of epidemiological, bio-
logical and clinical relevance. For example, the proportion
Table 3: Frequency of Pvmsp1 allelic variants found in segments F1, F2 and F3.
F1 F2 F3
Variant n Frequency Varianta n Frequency Variant n Frequency
A 4 0.038 Aa1 50 0.5 A 1 0.009
B 19 0.183 Aa3 6 0.06 B 12 0.112
C 44 0.423 Aa6 15 0.15 C 12 0.112
D 22 0.212 Aa7 4 0.04 D 82 0.766
E 15 0.144 Aa8 1 0.01
Aa9 1 0.01
Aa10 1 0.01
Ba1 6 0.06
Ba2 1 0.01
Ba3 5 0.05
Ba5 2 0.02
Ba6 4 0.04
Ba7 3 0.03
Ba10 1 0.01
Am1 38 0.38
Am2 6 0.06
Am3 2 0.02
Am4 4 0.04
Am5 11 0.11
Am6 2 0.02
Am8 14 0.14
Am9 1 0.01
Bm1 6 0.06
Bm2 3 0.03
Bm3 7 0.07
Bm4 2 0.02
Bm5 3 0.03
Bm8 1 0.01
a RFLP patterns obtained by digestion with Alu I or Mnl I were numbered in two series a1, a2, etc.. and m1, m2 etc..., respectively. A given pattern 
could be obtained irrespective of the size of the fragment amplified (A or B).Malaria Journal 2005, 4:20 http://www.malariajournal.com/content/4/1/20
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of hypnozoites and the timing and frequency of their acti-
vation, differ between temperate and tropical strains of
this parasite [28]. Resistance to drugs is linked to genetic
mutations of defined genes [29] and recently the Pvcs
repeat type was found to be associated with transmissibil-
ity by defined species of anophelines [30]. The ability to
differentiate genetically different parasite populations
would enhance a wide spectrum of investigations of the
biology and epidemiology of P. vivax.
In this article, the potential of two P. vivax genes, Pvcs and
Pvmsp1, as genetic markers, were assessed and practical
protocols for their use in genotyping parasites collected
from the field were described. PCR-based protocols tar-
geted four polymorphic regions from two genetic markers,
one from Pvcs and three from Pvmsp1, and were further
associated to RFLP analyses of two of these regions, the
repeat region of Pvcs and the F2 fragment of Pvmsp1, that
allow the division of parasite populations into an incre-
mental number of genetically distinct sub-groups.
For Pvmsp1, three polymorphic regions were independ-
ently assessed. The fragments F1, located at variable block
2 and F3 located at variable block 10, displayed moderate
allelic size variation, five and four types respectively. The
frequency of the size variants, in particular those of F3,
displayed a biased frequency distribution among the 100
Thai isolates considered in this study, thus undermining
their usefulness as genetic markers. Sequencing was
carried out for a subset of F1 and F3 fragments amplified
from the Thai isolates. This revealed that 13 F1 and 10 F2
allelic variants could actually be distinguished. These
results confirm the high degree of complex polymor-
phisms observed for Pvmsp1  block 2 and block 10
observed in 31 isolates collected in Thailand, Brazil,
Oceania and India, where 19 and 13 distinct allelic types
were observed for block 2 and block 10 respectively [27].
Thus it is likely that the F1 and F3 segments could be
exploited as useful genetic markers through the develop-
ment of type-specific oligonucleotides, that would then be
used in a series of nested PCR reactions. The amplified
large central F2 fragment, located between variable block
6 and 8, showed two size variants only. However, when
combined to RFLP analyses, using two restriction endonu-
cleases, the variants were subdivided into a total of 36 dif-
ferent allelic types. For Pvcs, populations were divided
into 10 subgroups through size and repeat type determi-
nation, and into 23 subgroups when sequence variations
in the pre- and post-repeat sequences were assessed by
RFLP.
Alignment of amino acid sequences of amplified F1 and F3 fragments of Pvmsp1 Figure 4
Alignment of amino acid sequences of amplified F1 and F3 fragments of Pvmsp1. Sequences were aligned against the largest frag-
ment obtained; dots represent identical residues and dashes represent gaps. Sequences obtained during this study are labelled 
by their GenBank accession numbers, while the Belem and Sal-1 sequences had been previously published (AF435594 and 
AF435593, respectively).Malaria Journal 2005, 4:20 http://www.malariajournal.com/content/4/1/20
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The conclusion of this work is that the polymorphic
repeat region of Pvcs and that of the Pvmsp1 F2 region can
be considered suitable genetic markers of P. vivax popula-
tions, alone or in combination. This is supported by the
fact that practical PCR-RFLP genotyping protocols
revealed the presence of numerous distinct allelic variants
in a sample of 100 isolates, among which they were ran-
domly distributed without evidence of linkage disequilib-
rium between the two loci.
Interesting epidemiological indications could be derived
from genotyping of the P. vivax isolates. Malaria is consid-
ered to be hypoendemic in Thailand where transmission,
confined to regions bordering Cambodia, Lao PDR and
Myanmar, rarely exceeds a few infective bites per person
per year. A study of P. falciparum diversity, based on three
genetic markers, in a refugee camp located in Thailand
close to the Myanmar border, revealed levels of diversity
and MOI (1.6, with mixed genotype infections observed
in 60 % of the isolates) that were higher than expected
from the low effective inoculation rates [31]. A recent
study of P. vivax parasites collected in the same region and
based on two genetic markers, showed that populations of
this parasite species were also highly diverse and mixed
genotype infections were observed in 35 % of the isolates
[32]. The results of the present study indicated that 26 %
of the isolates were of mixed genotype, with an overall
MOI for all 100 isolates of 1.29. It should be stated that
the three studies are not strictly comparable since the
number and type of genetic markers, the genotyping pro-
tocols and the collection strategies that were employed
differed. Furthermore, in the current study the origin of
the P. vivax isolates was not confined to a single area, since
the patients from whom blood was collected acquired
their infection in diverse endemic areas of Thailand.
Nonetheless, these studies indicated that the two biologi-
cally distinct parasite species have similar population
characteristics. The production of infectious gametocytes
early during the primary infection in P. vivax versus their
late appearance, following the acute phase, in P. falci-
parum, and the existence of hypnozoites solely in P. vivax,
might not be sufficient to explain the maintenance of
diversity in areas of low transmission. Substantially pro-
longed duration of the infections, probably as a result of
low level drug resistance leading to parasitological
(though not clinical) failures, as suggested for P. falci-
parum  [31], and/or an underestimation of the
transmission intensity, might underlie the high genetic
diversity and MOI observed for the two parasite species.
These two non-mutually exclusive scenarios are consistent
with the detection of a high level of mixed species infec-
tions observed in Thailand [33-36].
It is hoped that the methodologies presented here can be
adopted as standard protocols for the genotyping of P.
vivax parasites, not only for in vivo drug efficacy trials, but
also in field-based investigations aimed at elucidating the
biology, pathology and epidemiology of this important
parasite species.
Conclusion
These results indicate that the genotyping protocols pre-
sented can be useful in the assessment of in vivo drug effi-
cacy clinical trials conducted in endemic areas and for
epidemiological studies of P. vivax infections.
Table 4: Frequency of the F2 Pvmsp1 allelic variants classed 
following RFLP analysis.
Variant Size Alu I 
Pattern 
number
Mnl 
Pattern 
number
na Frequency
Aa A1 1 2 7 0.27
Ab A1 2 5 0.05
Ac A1 4 3 0.03
Ad A1 5 1 0.01
Ae A1 6 1 0.01
Af A1 8 1 2 0.12
Ag A1 9 1 0.01
Ah A3 1 4 0.04
Ai A3 2 1 0.01
Aj A3 4 1 0.01
Ak A6 1 3 0.03
Al A6 3 2 0.02
Am A6 5 8 0.08
An A6 6 1 0.01
Ao A6 8 1 0.01
Ap A7 1 2 0.02
Aq A7 5 2 0.02
Ar A8 1 1 0.01
As A9 1 1 0.01
At A1 0 8 1 0.01
Ba B1 1 2 0.02
Bb B1 2 1 0.01
Bc B1 3 1 0.01
Bd B1 4 1 0.01
Be B1 8 1 0.01
Bf B2 1 1 0.01
Bg B3 1 2 0.02
Bh B3 2 1 0.01
Bi B3 3 1 0.01
Bj B3 4 1 0.01
Bk B5 1 1 0.01
Bl B5 2 1 0.01
Bm B6 3 4 0.04
Bn B7 3 1 0.01
Bo B7 5 2 0.02
Bp B1 0 5 1 0.01
a Number of isolates where a particular pattern was observed 
amongst the 100 Thai isolates analysedMalaria Journal 2005, 4:20 http://www.malariajournal.com/content/4/1/20
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List of Abbreviations used
Pvcs-Circumsporozoite surface protein gene of Plasmo-
dium vivax
Pvmsp1-Merozoite surface protein 1 gene of Plasmodium
vivax
Pvmsp3α -Merozoite surface protein 3 alpha gene of Plas-
modium vivaxPCR-Polymerase Chain Reaction
RFLP-Restriction Fragment Length Polymorphism
Allele frequency of the distinct allelic variants of the F2 segment of Pvmsp1 observed in the 100 isolates from Thailand Figure 5
Allele frequency of the distinct allelic variants of the F2 segment of Pvmsp1 observed in the 100 isolates from Thailand. Allelic 
variants were defined according to the RFLP patterns observed. A. Variants were divided according to the digestions patterns 
obtained individually with each of the two restriction enzymes Alu I (a1, a2, etc...) or Mnl I (m1, m2, etc...) for A or B, the two 
different sized fragments amplified, as in Table 3. B) Variants were classed according to size and the combined RFLP patterns 
obtained for both restriction enzymes (Alu I and Mnl I), as in Table 4.Malaria Journal 2005, 4:20 http://www.malariajournal.com/content/4/1/20
Page 12 of 13
(page number not for citation purposes)
Authors' contributions
GS, NJW and SP designed the study. GS and SP were
responsible for the day-to-day supervision of the work.
ACG, FL and LR and MI collaborated to obtain and ana-
lyze DNA sequences. SL and SP were responsible for
patient recruitment and clinical management. MI devel-
oped the protocols with the help of GS, and carried out
the vast majority of the laboratory work. GS and MI ana-
lyzed the data and composed the manuscript. All authors
read and approved the final manuscript.
Acknowledgements
This study was part of the Wellcome Trust-Mahidol University-Oxford 
Tropical Medicine Research Programme supported by the Wellcome Trust 
of Great Britain.
References
1. Mendis K, Sina BJ, Marchesini P, Carter R: The neglected burden
of Plasmodium vivax malaria. Am J Trop Med Hyg 2001, 64(1-2
Suppl):97-106.
2. Hay SI, Guerra CA, Tatem AJ, Noor AM, Snow RW: The global dis-
tribution and population at risk of malaria: past, present, and
future. Lancet Infect Dis 2004, 4(6):327-336.
3. Nosten F, McGready R, Simpson JA, Thwai KL, Balkan S, Cho T, Hki-
rijaroen L, Looareesuwan S, White NJ: Effects of Plasmodium
vivax malaria in pregnancy. Lancet 1999, 354(9178):546-549.
4. Trape JF: The public health impact of chloroquine resistance
in Africa. Am J Trop Med Hyg 2001, 64(1-2 Suppl):12-17.
5. Rieckmann KH, Davis DR, Hutton DC: Plasmodium vivax resist-
ance to chloroquine? Lancet 1989, 2(8673):1183-1184.
6. Baird JK, Basri H, Purnomo, Bangs MJ, Subianto B, Patchen LC, Hoff-
man SL: Resistance to chloroquine by Plasmodium vivax in
Irian Jaya, Indonesia. Am J Trop Med Hyg 1991, 44(5):547-552.
7. Garavelli PL, Corti E: Chloroquine resistance in Plasmodium
vivax: the first case in Brazil. Trans R Soc Trop Med Hyg 1992,
86(2):128.
8. Thaithong S, Chan SW, Songsomboon S, Wilairat P, Seesod N, Sue-
blinwong T, Goman M, Ridley R, Beale G: Pyrimethamine resist-
ant mutations in Plasmodium falciparum. Mol Biochem Parasitol
1992, 52(2):149-157.
9. Myat Phone K, Myint O, Myint L, Thaw Z, Kyin Hla A, Nwe Nwe Y:
Emergence of chloroquine-resistant Plasmodium vivax in
Myanmar (Burma). Trans R Soc Trop Med Hyg 1993, 87(6):687.
10. Murphy GS, Basri H, Purnomo, Andersen EM, Bangs MJ, Mount DL,
Gorden J, Lal AA, Purwokusumo AR, Harjosuwarno S, et al.: Vivax
malaria resistant to treatment and prophylaxis with
chloroquine. Lancet 1993, 341(8837):96-100.
11. Garg M, Gopinathan N, Bodhe P, Kshirsagar NA: Vivax malaria
resistant to chloroquine: case reports from Bombay. Trans R
Soc Trop Med Hyg 1995, 89(6):656-657.
12. Baird JK, Leksana B, Masbar S, Fryauff DJ, Sutanihardja MA, Suradi,
Wignall FS, Hoffman SL: Diagnosis of resistance to chloroquine
by Plasmodium vivax: timing of recurrence and whole blood
chloroquine levels. Am J Trop Med Hyg 1997, 56(6):621-626.
13. Pukrittayakamee S, Chantra A, Simpson JA, Vanijanonta S, Clemens R,
Looareesuwan S, White NJ: Therapeutic responses to different
antimalarial drugs in vivax malaria. Antimicrob Agents Chemother
2000, 44(6):1680-1685.
14. Golenda CF, Li J, Rosenberg R: Continuous in vitro propagation
of the malaria parasite Plasmodium vivax. Proc Natl Acad Sci U
S A 1997, 94(13):6786-6791.
15. Chotivanich K, Silamut K, Udomsangpetch R, Stepniewska KA, Pukrit-
tayakamee S, Looareesuwan S, White NJ: Ex-vivo short-term cul-
ture and developmental assessment of Plasmodium vivax.
Trans R Soc Trop Med Hyg 2001, 95(6):677-680.
16. Snounou G, Beck HP: The use of PCR-genotyping in the assess-
ment of recrudescence or reinfection after antimalarial
treatment. Parasitology today 1998, 14(11):462-467.
17. Cui L, Escalante AA, Imwong M, Snounou G: The genetic diversity
of Plasmodium vivax populations.  Trends Parasitol 2003,
19(5):220-226.
18. Imwong M, Pukrittakayamee S, Looareesuwan S, Poirriez J, Pasvol G,
White NJ, Snounou G: Plasmodium vivax: polymerase chain
reaction amplification artifacts limit the suitability of
pvgam1 as a genetic marker. Exp Parasitol 2001, 99(3):175-179.
19. Bruce MC, Galinski MR, Barnwell JW, Snounou G, Day KP: Polymor-
phism at the merozoite surface protein-3alpha locus of Plas-
modium vivax: global and local diversity. Am J Trop Med Hyg
1999, 61(4):518-525.
20. Snounou G, Viriyakosol S, Zhu XP, Jarra W, Pinheiro L, do Rosario
VE, Thaithong S, Brown KN: High sensitivity of detection of
human malaria parasites by the use of nested polymerase
chain reaction. Mol Biochem Parasitol 1993, 61(2):315-320.
21. Mann VH, Huang T, Cheng Q, Saul A: Sequence variation in the
circumsporozoite protein gene of Plasmodium vivax
appears to be regionally biased.  Mol Biochem Parasitol 1994,
68(1):45-52.
22. Rongnoparut P, Supsamran N, Sattabongkot J, Suwanabun N, Rosen-
berg R: Phenotype and genotype diversity in the circumspo-
rozoite proteins of Plasmodium vivax in Thailand. Mol Biochem
Parasitol 1995, 74(2):201-210.
23. Rosenberg R, Wirtz RA, Lanar DE, Sattabongkot J, Hall T, Waters AP,
Prasittisuk C: Circumsporozoite protein heterogeneity in the
human malaria parasite Plasmodium vivax.  Science 1989,
245(4921):973-976.
24. Mann VH, Good MF, Saul AJ: Diversity in the circumsporozoite
protein of Plasmodium vivax: Does it matter?  Parasitology today
1995, 11:33-36.
25. del Portillo HA, Longacre S, Khouri E, David PH: Primary structure
of the merozoite surface antigen 1 of Plasmodium vivax
reveals sequences conserved between different Plasmodium
species. Proc Natl Acad Sci U S A 1991, 88(9):4030-4034.
26. Gibson HL, Tucker JE, Kaslow DC, Krettli AU, Collins WE, Kiefer
MC, Bathurst IC, Barr PJ: Structure and expression of the gene
for Pv200, a major blood-stage surface antigen of Plasmo-
dium vivax. Mol Biochem Parasitol 1992, 50(2):325-333.
27. Putaporntip C, Jongwutiwes S, Sakihama N, Ferreira MU, Kho WG,
Kaneko A, Kanbara H, Hattori T, Tanabe K: Mosaic organization
and heterogeneity in frequency of allelic recombination of
the Plasmodium vivax merozoite surface protein-1 locus.
Proc Natl Acad Sci U S A 2002, 99(25):16348-16353.
28. Garnham PC, Bray RS, Bruce-Chwatt LJ, Draper CC, Killick-Kendrick
R, Sergiev PG, Tiburskaja NA, Shute PG, Maryon M: A strain of
Plasmodium vivax characterized by prolonged incubation:
morphological and biological characteristics. Bull World Health
Organ 1975, 52(1):21-32.
29. Imwong M, Pukrittayakamee S, Renia L, Letourneur F, Charlieu JP,
Leartsakulpanich U, Looareesuwan S, White NJ, Snounou G: Novel
point mutations in the dihydrofolate reductase gene of Plas-
modium vivax: evidence for sequential selection by drug
pressure. Antimicrob Agents Chemother 2003, 47(5):1514-1521.
30. Gonzalez-Ceron L, Rodriguez MH, Santillan F, Chavez B, Nettel JA,
Hernandez-Avila JE, Kain KC: Plasmodium vivax: ookinete
destruction and oocyst development arrest are responsible
for Anopheles albimanus resistance to circumsporozoite
phenotype VK247 parasites. Exp Parasitol 2001, 98(3):152-161.
31. Paul RE, Hackford I, Brockman A, Muller-Graf C, Price R, Luxem-
burger C, White NJ, Nosten F, Day KP: Transmission intensity
and Plasmodium falciparum diversity on the northwestern
border of Thailand. Am J Trop Med Hyg 1998, 58(2):195-203.
32. Cui L, Mascorro CN, Fan Q, Rzomp KA, Khuntirat B, Zhou G, Chen
H, Yan G, Sattabongkot J: Genetic diversity and multiple infec-
tions of Plasmodium vivax malaria in Western Thailand. Am
J Trop Med Hyg 2003, 68(5):613-619.
33. Mayxay M, Pukritrayakamee S, Chotivanich K, Imwong M, Looareesu-
wan S, White NJ: Identification of cryptic coinfection with Plas-
modium falciparum in patients presenting with vivax
malaria. Am J Trop Med Hyg 2001, 65(5):588-592.
34. Siripoon N, Snounou G, Yamogkul P, Na-Bangchang K, Thaithong S:
Cryptic Plasmodium falciparum parasites in clinical P. vivax
blood samples from Thailand. Trans R Soc Trop Med Hyg 2002,
96(1):70-71.
35. Mayxay M, Pukrittayakamee S, Newton PN, White NJ: Mixed-spe-
cies malaria infections in humans.  Trends Parasitol 2004,
20(5):233-240.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Malaria Journal 2005, 4:20 http://www.malariajournal.com/content/4/1/20
Page 13 of 13
(page number not for citation purposes)
36. Snounou G, White NJ: The co-existence of Plasmodium: side-
lights from falciparum and vivax malaria in Thailand. Trends
Parasitol 2004, 20(7):333-339.